Abstract
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system. Alemtuzumab (ALEM) is an immunosuppressant for highly-active (HA) MS. We present efficacy/safety profile of ALEM in a real-world setting.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
